Search
Dihydroergocristine
go.drugbank.com/drugs/DB13345Approved[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.
Categories: Ergot Alkaloids and DerivativesLevomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. … [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.
Categories: Milnacipran and enantiomer, Serotonin and Noradrenaline Reuptake InhibitorsNabiximols
go.drugbank.com/drugs/DB14011InvestigationalSativex® is available in a 1:1 formulation of THC:CBD as an oro-mucosal pump spray used for treatment of neuropathic pain from Multiple Sclerosis (MS) and for intractable cancer pain. … Nabiximols (tradename Sativex®) is a whole plant extract from the Cannabis species _Cannabis sativa L._ that has been purified into the active components CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol
Categories: Cannabinoids and similarsFlorquinitau (18F)
go.drugbank.com/drugs/DB19215ApprovedInvestigational[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … [L64052] After intravenous injection, florquinitau F 18 crosses the blood-brain barrier and accumulates in brain regions containing tau NFTs, allowing their distribution to be visualized and interpreted
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521] … [L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Categories: diflucortolone and antiseptics, Hormones, Hormone Substitutes, and Hormone AntagonistsTasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalTasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. … By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism
Categories: Hypnotics and SedativesMethyprylon
go.drugbank.com/drugs/DB01107ApprovedIllicitWithdrawnMethyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.
Categories: Hypnotics and SedativesDelafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationaland Community Acquired Pneumonia, among others. … It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.
Benziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnIt was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636]. … Benziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout [A175630].